| Ytd | 48.14% | |
| 1y | -12.59% |
| Open | 4.53 | Prev Close | 4.57 | Low | 4.50 | High | 4.59 | Mkt Cap | 77.30M |
| Vol | 9.21K | Avg Vol | 44.19K | EPS | -0.78 | P/E | -5.83 | Forward P/E | -27.22 |
| Beta | 0.68 | Short Ratio | 0.04 | Inst. Own | 1.28% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-08 | 50-d Avg | 4.80 | 200-d Avg | 3.95 | 1yr Est | 8.00 |
ATHE News
– Newly granted patent extends protection for ATH434 to at least 2045, significantly enhancing its
Craig-Hallum analyst Adam Vogel initiates coverage on Alterity Therapeutics (NASDAQ:ATHE) with a
MELBOURNE, Australia and SAN FRANCISCO, Aug. 06, 2026 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX
Highlights FDA End-of-Phase 2 (EOP2) meeting minutes confirmed a registrational pathway for ATH434 i
MELBOURNE, Australia and SAN FRANCISCO, July 21, 2026 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX
– Official FDA minutes confirm the previously announced End-of-Phase 2 meeting outcomes and provide
Alterity Therapeutics Limited (NASDAQ:ATHE) stock is up during Tuesday's session as the biotechnolog
– Successful End-of-Phase 2 meeting with FDA agreeing on key elements of the proposed Phase 3 design
– Alterity's novel imaging and biomarker approach positions the Company at the forefront of clinical
– Peer-reviewed study from the bioMUSE Natural History Study shows advanced MRI method detects disea
MELBOURNE, Australia and SAN FRANCISCO, May 07, 2026 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX:
Highlights Aligned with the FDA in two Positive Type C meetings supporting key elements of the plann
Alterity Therapeutics Limited (ATHE) Discusses Phase II Data and Development Strategy for ATH434 in
MELBOURNE, Australia and SAN FRANCISCO, April 27, 2026 (GLOBE NEWSWIRE) -- Alterity Therapeutics (AS
- ATH434 reduced functional decline vs placebo at Week 52 on MuSyCA, a newly described MSA composite
MELBOURNE, Australia and SAN FRANCISCO, April 17, 2026 (GLOBE NEWSWIRE) -- Alterity Therapeutics (AS
NovoCure (NASDAQ: NVCR - Get Free Report) and Alterity Therapeutics (NASDAQ: ATHE - Get Free Report)
Alterity Therapeutics Limited - Sponsored ADR (NASDAQ: ATHE - Get Free Report) was the recipient of
Alignment reached on key elements of ATH434 Phase 3 development program Alignment reached on key ele
Alterity Therapeutics (NASDAQ: ATHE) outlined its development strategy for lead drug candidate ATH43
Alterity Therapeutics Limited - Sponsored ADR (NASDAQ: ATHE - Get Free Report) saw a large growth in
Shares of Daktronics, Inc. (NASDAQ: DAKT) moved lower during Tuesday’s session following weak quarte
Shares of GitLab Inc. (NASDAQ: GTLB) rose sharply in pre-market trading after the company posted be
On Wednesday, 479 stocks made new 52-week lows.
On Wednesday, 807 companies reached new 52-week lows.
Stocks That Hit 52-Week Lows On Monday